ERBB2 and breast carcinoma: Further, a different phase II clinical study is also assessing ARX-788 for HER2-positive metastatic breast tumor therapy (NCT05018676), HER2-mautated or HER2-overexpressed cancers (NCT05041972), HER2-low breast tumors (NCT05018676), and HER2-positive breast cancers with brain metastasis (NCT05018702) [75].